Table 1.
Baseline characteristics of UK Biobank Pharma Proteomics Project participants included in the present study (n = 44,313)
| UKB-PPP participants (n = 44,313) | |
|---|---|
| Age at blood draw, years | 56.4 ± 8.2 |
| Female, n | 24,701 (55.7%) |
| Race/ethnicity, n | – |
| Asian | 942 (2.1%) |
| Black | 1,051 (2.4%) |
| White | 41,481 (93.6%) |
| Mixed | 300 (0.7%) |
| Other | 539 (1.2%) |
| Smoking status, n | – |
| Never | 24,709 (55.8%) |
| Previous | 14,932 (33.7%) |
| Current | 4,672 (10.5%) |
| BMI, kg m−² | 27.3 ± 4.7 |
| Blood pressure, mm Hg | – |
| Systolic blood pressure | 139.5 ± 19.6 |
| Diastolic blood pressure | 82.3 ± 10.6 |
| Blood biochemistry, mg dl−1 | – |
| Total cholesterol | 221.4 ± 43.8 |
| LDL cholesterol | 138.3 ± 33.4 |
| HDL cholesterol | 56.4 ± 14.7 |
| Triglycerides | 129.8 (92.0 to 188.1) |
| Creatinine | 0.82 ± 0.19 |
| Type 2 diabetes mellitus, n | 1,218 (2.7%) |
| Medication use, n | – |
| Cholesterol-lowering medication use | 6,544 (14.8%) |
| Antihypertensive medication use | 6,214 (14.0%) |
| Townsend deprivation index | −2.08 (−3.63 to 0.70) |
Continuous variables are summarized as mean ± s.d. or median (IQR), as appropriate. Categorical variables are summarized as n (%).